http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113234090-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2021-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113234090-B |
| titleOfInvention | Compounds targeting ubiquitination to degrade FoxM1 or their pharmaceutically acceptable salts, preparation methods and uses |
| abstract | The present invention discloses a compound for targeted degradation of FoxM1 or a pharmaceutically acceptable salt thereof, a preparation method and use thereof. The structure is shown in general formula (I). The experimental results show that, compared with the FoxM1 inhibitor FDI-6, the compounds of the present invention can effectively degrade the transcription factor FoxM1, especially the compound F-8, and show better anti-breast cancer activity at both cell and animal levels. |
| priorityDate | 2021-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.